Agreement expands Mycovia?s commercialization that is global for VT-1161 to Europe, Latin America, Australia, Russia and Commonwealth of Independent States
Mycovia continues to quickly develop VT-1161 as a possible first FDA-approved remedy for recurrent candidiasis that is vulvovaginal
DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced it offers entered into a license that is exclusive development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, a dental product that is antifungal, happens to be in period 3 medical trials when it comes to remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million females global every year.
?We are excited to partner with Gedeon Richter, an organization with strong market leadership in women?s health, to produce and commercialize VT-1161, our prospective first treatment that is FDA-approved RVVC,? said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. Czytaj dalej